← 返回

Ant2 缺陷驱动的代谢重编程增强小鼠 T 细胞功能和抗肿瘤免疫

英文原题:Metabolic reprogramming driven by Ant2 deficiency augments T Cell function and anti-tumor immunity in mice.

查看英文原题

Metabolic reprogramming driven by Ant2 deficiency augments T Cell function and anti-tumor immunity in mice.

PubMed 2025/05/08(内容时间) Nat Commun Q1 · IF 18.1(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

T细胞活化需要NAD+生成大幅增加,往往超出氧化磷酸化(OXPHOS)的能力。为研究T细胞如何适应这一代谢挑战,我们构建了T细胞特异性ADP/ATP转位酶-2敲除(Ant2-/-)小鼠。Ant2是介导线粒体与细胞质之间ADP/ATP交换的关键蛋白,其缺失通过限制ATP合酶活性诱导OXPHOS受限,从而阻碍NAD+再生。有趣的是,与野生型对照相比,Ant2-/-初始T细胞表现出增强的活化、增殖和效应功能。代谢谱分析显示,这些T细胞采用了一种活化样代谢程序,伴有线粒体生物发生和合成代谢增加。最后,在野生型T细胞中药理学抑制ANT可重现Ant2-/-表型,并改善小鼠模型中的过继性T细胞癌症治疗。因此,我们的研究结果表明,Ant2缺陷T细胞绕过了活化所需的典型代谢重编程,导致T细胞功能增强,并凸显了靶向ANT用于免疫调节的治疗潜力。

展开英文摘要原文

T cell activation requires a substantial increase in NAD + production, often exceeding the capacity of oxidative phosphorylation (OXPHOS). To investigate how T cells adapt to this metabolic challenge, we generate T cell-specific ADP/ATP translocase-2 knockout (Ant2 -/- ) mice. Loss of Ant2, a crucial protein mediating ADP/ATP exchange between mitochondria and cytoplasm, induces OXPHOS restriction by limiting ATP synthase activity, thereby impeding NAD + regeneration.

Interestingly, Ant2 -/- naïve T cells exhibit enhanced activation, proliferation and effector functions compared to wild-type controls. Metabolic profiling reveals that these T cells adopt an activated-like metabolic program with increased mitobiogenesis and anabolism. Lastly, pharmacological inhibition of ANT in wild-type T cells recapitulates the Ant2 -/- phenotype and improves adoptive T cell therapy of cancer in mouse models.

Our findings thus suggest that Ant2-deficient T cells bypass the typical metabolic reprogramming required for activation, leading to enhanced T cell function and highlighting the therapeutic potential of targeting ANT for immune modulation.

论文信息

作者
Yosef O、Cohen-Daniel L、Shamriz O、Bar-On Z、Salaymeh W、Saragovi A、Abramovich I、Agranovich B
第一作者单位
The Institute for Medical Research Israel-Canada (IMRIC), Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.Israel
通讯作者单位
The Institute for Medical Research Israel-Canada (IMRIC), Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel. michaelb@ekmd.huji.ac.il.Israel
期刊
Nature communications2025 May 8
原文标识
PubMed 40341170 · DOI 10.1038/s41467-025-59310-3